Fig. 4: ΔgD-2 vaccination protects from establishing HSV-2 sacral ganglia latent reservoir but has no effect on the HSV-1 trigeminal ganglia reservoir. | npj Vaccines

Fig. 4: ΔgD-2 vaccination protects from establishing HSV-2 sacral ganglia latent reservoir but has no effect on the HSV-1 trigeminal ganglia reservoir.

From: Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity

Fig. 4

At the time of death or sacrifice (D14 post-HSV-2 challenge), trigeminal (a) and sacral (b) ganglia were isolated from female (closed symbols) and male (open symbols) mice, and HSV-1 and HSV-2 DNA quantified by qPCR using serotype-specific primers. Mice that succumbed to HSV-2 superinfection are indicated by a crossed-through symbol in b. HSV-1+, ΔgD-2 n = 25; HSV-1+, rgD-2-alum/MPL n = 10; HSV-1+, VD60 n = 15; Naïve, ΔgD-2 n = 10; Naïve, VD60 n = 8 from two independent experiments. The quantity of viral DNA detected was compared by ANOVA with correction for multiple comparison (**p < 0.01, ****p < 0.001, ns not significant), and means are indicated.

Back to article page